Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies

Efficacy exposure–response relationships of the CCR5 antagonist maraviroc were evaluated across two phase III clinical trials. This post-hoc analysis used 48-week efficacy data from 841 treatment-experienced patients infected with CCR5-tropic human immunodeficiency virus type 1 (HIV-1), identified b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacqmin, P, Wade, J R, Weatherley, B, Snoeck, E, Marshall, S, McFadyen, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828006/
https://www.ncbi.nlm.nih.gov/pubmed/23945605
http://dx.doi.org/10.1038/psp.2013.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828006/
https://www.ncbi.nlm.nih.gov/pubmed/23945605
http://dx.doi.org/10.1038/psp.2013.42

Ejemplares similares